Obinutuzumab for the treatment of non-Hodgkin lymphomas
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology
Rituximab: modes of action, remaining dispute and future perspective | Future Oncology
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. - Abstract - Europe PMC
![PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/33f339e9d609e1fa7d39a952cafd3e938b2119d3/3-Table2-1.png "PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar")
PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar
Obinutuzumab - an overview | ScienceDirect Topics
Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. - Abstract - Europe PMC
The Emerging Role of Obinutuzumab in the Treatment of B-Cell Lymphoid Malignancies
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma - Clinical Lymphoma, Myeloma and Leukemia
New developments in the treatment of chronic lymphocytic leukemia: rol | TCRM
Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL | Research To Practice
A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library
Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions | Research To Practice
A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library
Venetoclax (Venclexta®) + Obinutuzumab (Gazyva®) for CLL | ChemoExperts
Obinutuzumab Overview - Creative Biolabs
GAZYVA® (obinutuzumab) Proposed Mechanism of Action | CLL
The clinical development of obinutuzumab for the treatment of follicul | CMAR
GAZYVA® (obinutuzumab) Proposed Mechanism of Action | CLL
Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram
Mechanisms of action of anti-CD20 monoclonal antibodies. Abbreviation:... | Download Scientific Diagram
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways - ScienceDirect
